Patients with histological confirmed epithelia ovarian cancer
Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
FFPE tumor tissue available
You may not be if
Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Clareo Health | Clinical Pre-screening Protocol for Ovarian Cancer
